Therapeutic response and safety of radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients
Salvato in:
| Pubblicato in: | Medical Oncology vol. 41, no. 9 (Sep 2024), p. 226 |
|---|---|
| Autore principale: | |
| Altri autori: | , , |
| Pubblicazione: |
Springer Nature B.V.
|
| Soggetti: | |
| Accesso online: | Citation/Abstract Full Text - PDF |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3092502672 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1357-0560 | ||
| 022 | |a 1559-131X | ||
| 022 | |a 0736-0118 | ||
| 024 | 7 | |a 10.1007/s12032-024-02466-7 |2 doi | |
| 035 | |a 3092502672 | ||
| 045 | 2 | |b d20240901 |b d20240930 | |
| 084 | |a 38745 |2 nlm | ||
| 100 | 1 | |a Ashfaq, Wardah |u INMOL Hospital, Department of Nuclear Medicine, Lahore, Pakistan | |
| 245 | 1 | |a Therapeutic response and safety of radioligand therapy with <sup>177</sup>Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients | |
| 260 | |b Springer Nature B.V. |c Sep 2024 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Prostate cancer is one of the most common cancers and leading cause of death due to cancer across the globe. This persuaded researchers to devise innovative treatment modalities that may prove effective, safe, and demonstrate better outcomes in terms of patient morbidity and survival. The advancement in theranostics such as lutetium-177 (177Lu)-PSMA-617 radioligand therapies can target prostate cancer cells causing negligible or no damage to most of the normal tissues in patients. It has been proven to effectively improve the quality of life and progression-free survival. In this study, stage IV metastatic castration-resistant prostate cancer patients were treated with 177Lu-PSMA-617, and the therapeutic response and safety of 177Lu-PSMA-617 radioligand therapy were evaluated six months after the treatment. Additionally, molecular docking studies were also conducted to find the possible mechanism at the molecular level that causes the effectiveness of 177Lu-PSMA-617 in prostate cancer. | |
| 653 | |a Prostate cancer | ||
| 700 | 1 | |a Rehman, Khurram |u Forman Christian College (A Chartered University), Department of Pharmacy, Lahore, Pakistan (GRID:grid.444905.8) (ISNI:0000 0004 0608 7004) | |
| 700 | 1 | |a Shahid, Abubaker |u INMOL Hospital, Department of Oncology, Lahore, Pakistan (GRID:grid.444905.8) | |
| 700 | 1 | |a Younis, Muhammad Numair |u INMOL Hospital, Department of Nuclear Medicine, Lahore, Pakistan (GRID:grid.444905.8) | |
| 773 | 0 | |t Medical Oncology |g vol. 41, no. 9 (Sep 2024), p. 226 | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3092502672/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3092502672/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |